GlobeNewsWire
16 Feb 2026, 14:38 UTC · 31w ago
Verdict
Headline takes no side. We score VTGN −1.00 across three claims — strongly bearish.
−1.00strongly bearish
More negative than 95% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Vistagen's PALISADE-3 Phase 3 study of intranasal fasedienol failed to demonstrate a statistically significant improvement on its primary endpoint.
So whatFailure of a Phase 3 trial for a lead product candidate is a catastrophic event for a clinical-stage biopharma company, typically leading to massive valuation loss.
More negative than 99% of claims this week
Vistagen shares fell more than 80% following the announcement that the PALISADE-3 trial did not achieve its primary or secondary endpoints.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 99% of claims this week
The Portnoy Law Firm has initiated a class action lawsuit alleging Vistagen made misleading statements regarding the likelihood of Phase 3 success for fasedienol.
More negative than 86% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is facing a class action lawsuit following a failed Phase 3 clinical trial and an 80% drop in share price.
More negative than 85% of ticker scores this week
The company is being advised of a class action lawsuit on behalf of investors.
More negative than 85% of ticker scores this week
The company is being advised of a class action lawsuit on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
2h ago
−47.2%
Price agrees with the score
$0.2670 vs $0.5056 close before publication (Feb 13) · not market-adjusted
VTGN chart →
